Nerissa Kreher
CIK 1741850 · Chief Medical Officer · last filed 2026-07-02
Nerissa Kreher is a Chief Medical Officer who has filed 43 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing, for XERS, was dated Jul 2, 2026. Across all open-market trades the lifetime net is −$988.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TRDA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
275 SHORELINE DRIVE, SUITE 500
REDWOOD CITY, CA 94065
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XERS | Director | 33,582 | $16.30 | $547.4K | $0 | 1 | 2026-07-02 |
| RZLT | Director | 58,576 | $4.05 | $237.2K | $10.0K | 7 | 2025-11-21 |
| TRDA | Chief Medical Officer | 41,330 | $5.26 | $217.4K | -$998.2K | 15 | 2023-09-06 |
| Tectonic Therapeutic, Inc. (AVRO) Delisted | Chief Medical Officer | 245 | $16.80 | $4.1K | $0 | 1 | 2018-10-10 |
Recent Filings
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | XERS | Grant (A) | +33,582 | $0 | EDGAR |
| 2025-11-21 | RZLT | Grant (A) | +21,000 | $0 | EDGAR |
| 2025-06-23 | RZLT | Buy (P) | +3,076 | $10.0K | EDGAR |
| 2025-06-13 | RZLT | Grant (A) | +9,000 | $0 | EDGAR |
| 2025-02-19 | RZLT | Grant (A) | +25,500 | $0 | EDGAR |
| 2024-04-30 | TRDA | Notice (144) | −1,200 | -$14.6K | EDGAR |
| 2024-04-29 | TRDA | Notice (144) | −13,729 | -$168.5K | EDGAR |
| 2024-04-26 | TRDA | Notice (144) | −3,400 | -$42.5K | EDGAR |
| 2024-04-25 | TRDA | Notice (144) | −12,483 | -$152.5K | EDGAR |
| 2024-04-24 | TRDA | Notice (144) | −3,791 | -$47.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.